Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Jose L. Jimenez, Mourad Tighiouart, Mauro Gasparini

Journal title: Biometrical Journal

Journal publisher: John Wiley & Sons Ltd.

Published year: 2018

DOI identifier: 10.1002/bimj.201700166

ISSN: 0323-3847